| Literature DB >> 36010320 |
Fan Yang1, Wen Ren2, Dan Wang3, Yan Yan1, Yuan-Lin Deng1, Zhen-Wen Yang4, Tie-Lian Yu1, Dong Li1, Zhang Zhang1.
Abstract
BACKGROUND: Pulmonary hypertension (PH) is known to alter the biventricular shape and temporal phases of the cardiac cycle. The presence of interventricular septal (IVS) displacement has been associated with the severity of PH. There has been limited cardiac magnetic resonance (CMR) data regarding the temporal parameters of the cardiac cycle in PH. This study aimed to quantify the temporal changes in the cardiac cycle derived from CMR in PH patients with and without IVS displacement and sought to understand the mechanism of cardiac dysfunction in the cardiac cycle.Entities:
Keywords: cardiac cycle; cardiovascular physiological phenomena; cine; magnetic resonance imaging; pulmonary hypertension; ventricular function
Year: 2022 PMID: 36010320 PMCID: PMC9407232 DOI: 10.3390/diagnostics12081970
Source DB: PubMed Journal: Diagnostics (Basel) ISSN: 2075-4418
Figure 1Patient flowchart. PH, pulmonary hypertension; CMR, cardiac magnetic resonance; RHC, right heart catheterization; IVSND, pulmonary hypertension patients without interventricular septum displacement; IVSD, pulmonary hypertension patients with interventricular septum displacement.
Demographic, clinical and RHC characteristics in the health control and PH patients.
| HC ( | IVSND ( | IVSD ( | |
|---|---|---|---|
|
| |||
| Female, | 20 (90.9) | 14 (93.3) | 27 (81.8) |
| Age, years | 43 (35–49) | 52 (37–62) | 40 (32–62) |
| PAH/CTEPH | -- | 8/21 | 7/11 |
| WHO FC I/II/III/IV | -- | 0/14/1/0 | 0/13/17/3 ### |
| 6MWD, m | -- | 444 (302–463) | 235 (157–339) ### |
| NT-proBNP, pg/mL | -- | 97 (56–245) | 1678 (634–1961) ### |
| HR, bpm | 68 (63–73) | 71 (66–79) | 84 (78–93) *** # |
| BSA, m2 | 1.65 (1.58–1.77) | 1.66 (1.51–1.75) | 1.69 (1.50–1.76) |
| Low-risk/intermediate and high risk | -- | 9/6 | 3/30 |
|
| |||
| mPAP, mmHg | -- | 39 (33–46) | 54 (41–62) ## |
| PVR, Wood | -- | 10 (7–14) | 16 (11–21) ## |
| CI, L/min/m2 | -- | 2.3 (2.1–3.1) | 1.9 (1.5–2.5) # |
| mRAP, mmHg | -- | 5 (3–6) | 6 (5–9) # |
| PAWP, mmHg | -- | 10 (7–12) | 9 (6–10) |
*** p < 0.001: versus HC; # p < 0.05, ## p < 0.01, ### p < 0.001: versus IVSND. HC, health control; IVSND, pulmonary hypertension patient without interventricular septum displacement; IVSD, pulmonary hypertension patient with interventricular septum displacement; HR, heart rate; BSA, body surface area; WHO FC, World Health Organization functional classification; 6MWD, 6 min walking distance; NT-proBNP, N-terminal prohormone of the brain natriuretic peptide; PAH, pulmonary arterial hypertension; CTEPH, chronic thromboembolic pulmonary hypertension; RHC, right heart catheterization; mPAP, mean pulmonary arterial pressure; PVR, pulmonary vascular resistance; CI, cardiac index; mRAP, mean right atrium pressure; PAWP, pulmonary arterial wedge pressure.
CMR-derived morphologic and functional parameter characteristics in the health control and PH patients.
| HC ( | IVSND ( | IVSD ( | |
|---|---|---|---|
| RVEDVI, mL/m2 | 81 (71–87) | 68 (61–93) | 117 (104–140) *** ### |
| RVESVI, mL/m2 | 37 (32–43) | 43 (36–49) | 84 (66–95) *** ### |
| RVSVI, mL/m2 | 42 (38–49) | 35 (27–42) | 37 (29–47) |
| RVEF, % | 52 (50–60) | 45 (38–50) * | 31 (25–40) *** ## |
| RVMMI, g/m2 | 13 (10–17) | 17 (13–19) | 27 (20–31) *** ## |
| LVEDVI, mL/m2 | 80 (72–90) | 68 (53–78) | 54 (42–48) *** |
| LVESVI, mL/m2 | 33 (29–41) | 24 (21–35) | 26 (17–29) *** |
| LVSVI, mL/m2 | 45 (42–52) | 44 (32–50) | 30 (23–39) *** # |
| LVEF, % | 57 (52–67) | 61 (58–64) | 57 (53–61) |
| LVMMI, g/m2 | 40 (37–48) | 41 (36–47) | 42 (36–48) |
| VMI | 0.34 (0.27–0.42) | 0.42 (0.30–0.46) | 0.61 (0.48–0.76) *** ## |
| CIVS | 0.07 (0.06–0.07) | 0.06 (0.04–0.07) | 0.01 (−0.01–0.02) *** ### |
| CR | 1.00 (0.95–1.04) | 0.88 (0.71–0.92) | 0.24 (−0.23–0.45) *** ### |
* p < 0.05, *** p < 0.001: versus HC; # p < 0.05, ## p < 0.01, ### p < 0.001: versus IVSND; CMR, cardiac magnetic resonance; HC, health control; IVSND, pulmonary hypertension patient without interventricular septum displacement; IVSD, pulmonary hypertension patient with interventricular septum displacement; RV, right ventricle; LV, left ventricle; EDVI, end-diastolic volume index; ESVI, end-systolic volume index; SVI, stroke volume index; EF, ejection fraction; MMI, myocardial mass index; VMI, ventricular mass index; CIVS, interventricular septal curvature; CR, curvature ratio.
Figure 2The trend of the percentage changes in the RV (a) and LV (b) function from the HC to IVSD group. All of the values of the coordinate points were calculated from the percentage change of the median of the parameters in the IVSND and IVSD groups using the HC as the baseline. HC, health control; IVSND, pulmonary hypertension patients without interventricular septum displacement; IVSD, pulmonary hypertension patients with interventricular septum displacement; RV, right ventricle; LV, left ventricle; EDVI, end-diastolic volume index; ESVI, end-systolic volume index; SVI, stroke volume index; EF, ejection fraction; MMI, myocardial mass index; VMI, ventricular mass index.
CMR-derived temporal parameters of the three groups.
| Temporal Parameters | HC ( | IVSND ( | IVSD ( |
|---|---|---|---|
| PO, % | 6.1 (5.6–6.2) | 6.0 (1.2–10.8) | 1.3 (−3.4–6.2) |
| PC, % | 41.0 (36.2–41.3) | 40.8 (36.1–41.3) | 36.3 (33.2–38.9) |
| AO, % | 6.1 (4.8–6.2) | 6.0 (1.1–10.7) | 1.2 (−3.5–6.2) * |
| AC, % | 41.0 (36.1–41.2) | 36.1 (36.0–41.0) | 36.1 (31.5–36.3) ** |
| MO, % | 46.1 (41.1–51.0) | 46.2 (41.3–51.5) | 46.4 (43.8–48.4) |
| MC, % | 101.0 (96.2–101.1) | 101.0 (91.5–101.1) | 91.6 (86.7–96.3) *** # |
| TO, % | 46.1 (41.1–51.0) | 46.2 (45.9–51.2) | 51.3 (46.5–54.0) *** # |
| TC, % | 101.1 (99.7–101.1) | 101.0 (91.5–101.1) | 96.2 (91.5–96.4) *** |
| ICTRV, % | 5.0 (4.9–5.3) | 5.00 (4.9–10.0) | 5.0 (4.9–10.0) |
| ETRV, % | 35.0 (32.4–38.1) | 30.0 (30.0–40.0) | 35.0 (30.1–40.0) |
| IRTRV, % | 5.0 (4.9–5.3) | 9.9 (5.1–15.0) | 15.0 (10.1–19.9) *** # |
| FTRV, % | 55.0 (50.0–56.3) | 50.0 (45.0–55.0) | 44.2 (35.7–49.9) *** # |
| ICTLV, % | 5.0 (5.0–10.0) | 5.0 (4.9–10.0) | 9.9 (5.0–10.1) |
| ETLV, % | 35.0 (30.0–35.6) | 30.0 (30.0–35.0) | 35.0 (30.0–35.1) |
| IRTLV, % | 5.1 (5.0–10.0) | 9.9 (5.1–15.0) | 13.4 (10.0–15.0) *** |
| FTLV, % | 52.5 (49.9–55.1) | 50.1 (39.9–60.0) | 45.1 (40.1–50.0) ** |
* p < 0.05, ** p < 0.01, *** p < 0.001: versus HC; # p < 0.05: versus IVSND; HC, health control; IVSND, pulmonary hypertension patient without interventricular septum displacement; IVSD, pulmonary hypertension patient with interventricular septum displacement; RV, right ventricle; LV, left ventricle; P, pulmonary artery valve; A, aortic valve; M, mitral valve; T, tricuspid valve; ICT, isovolumetric contraction time; IRT, isovolumetric relaxation time; ET, ejection time; FT, filling time.
Figure 3Temporal changes between the HC, IVSND and IVSD in the right ventricle-pulmonary artery system (a) and left ventricle-aorta system (b). * p < 0.05, ** p < 0.01, *** p < 0.001: versus HC; # p < 0.05: versus IVSND; P, pulmonary artery valve; A, aortic valve; M, mitral valve; T, tricuspid valve; ICT, isovolumetric contraction time; IRT, isovolumetric relaxation time; ET, ejection time; FT, filling time; HC, health control; IVSND, pulmonary hypertension patients without interventricular septum displacement; IVSD, pulmonary hypertension patients with interventricular septum displacement.
Spearman correlations r between the CMR data and RHC data.
| mPAP | PVR | CI | Civs | |
|---|---|---|---|---|
| RVEDVI | 0.19 | 0.36 * | −0.35 * | −0.72 *** |
| RVESVI | 0.34 * | 0.53 ** | −0.50 *** | −0.79 *** |
| RVEF | −0.50 ** | −0.56 ** | 0.52 *** | 0.67 *** |
| RVMMI | 0.25 | 0.43 ** | −0.41 ** | −0.67 ** |
| LVEDVI | −0.50 ** | −0.41 ** | 0.40 ** | 0.44 *** |
| LVESVI | −0.39 ** | −0.32 * | 0.35 * | 0.29 *** |
| LVSVI | −0.51 ** | −0.43 ** | 0.39 ** | 0.48 * |
| VMI | 0.41 ** | 0.46 ** | −0.44 ** | −0.66 *** |
| IRTRV | 0.27 | 0.38 ** | −0.34 * | −0.49 *** |
| FTRV | −0.46 ** | −0.52 *** | 0.47 ** | 0.55 *** |
* p < 0.05, ** p < 0.01, *** p < 0.001. CMR, cardiac magnetic resonance; RHC, right heart catheterization; RV, right ventricle; LV, left ventricle; EDVI, end-diastolic volume index; ESVI, end-systolic volume index; SVI, stroke volume index; EF, ejection fraction; MMI, myocardial mass index; VMI, ventricular mass index; mPAP, mean pulmonary arterial pressure; PVR, pulmonary vascular resistance; CI, cardiac index; CIVS, interventricular septal curvature. IRT, isovolumetric relaxation time; FT, filling time.
Multiple linear regression analysis for RVEF.
| Variates | Unstandardized Coefficients | Standardized Coefficients |
| ||
|---|---|---|---|---|---|
| B (95% CI) | Std. Error | Beta | |||
| IRTRV | −0.456 (−0.990–−0.246) | 0.188 | −0.293 | −2.426 | 0.019 |
| LVEF | 0.490 (0.128–0.852) | 0.180 | 0.308 | 2.728 | 0.009 |
| PVR | −0.618 (−0.835–−0.077) | 0.185 | −0.403 | −3.350 | 0.002 |
The correlation coefficient between the result of the model and the CMR-derived RVEF was as follow, R = 0.667, R2 = 0.444, adjusted R2 = 407, F = 11.733, p < 0.001. RVEF, right ventricular ejection fraction; LVEF, left ventricular ejection fraction; RV, right ventricle; IRT, isovolumetric relaxation time.
Comparison of the CMR-derived indices and RHC characteristics of the PH patients based on risk stratification.
| Variates | Low Risk ( | Intermediate and High Risk ( | |
|---|---|---|---|
| RVEDVI, mL/m2 | 89 (66–93) | 112 (91–135) | 0.008 * |
| RVESVI, mL/m2 | 47 (36–53) | 80 (57–94) | 0.001 * |
| RVEF, % | 46 (40–50) | 32 (27–40) | <0.001 * |
| RVMASSI, g/m2 | 17 (14–23) | 23 (19–30) | 0.012 * |
| LVEDVI, mL/m2 | 70 (56–81) | 55 (43–70) | 0.034 * |
| LVSVI, mL/m2 | 41 (31–53) | 32 (23–41) | 0.024 * |
| VMI | 0.45 (0.32–0.50) | 0.60 (0.44–0.72) | 0.022 * |
| CR | 0.78 (0.34–0.91) | 0.29 (−0.21–0.69) | 0.017 * |
| TO, % | 46.2 (42.5–51.1) | 51.3 (46.4–55.2) | 0.005 * |
| IRTRV, % | 9.9 (5.1–13.8) | 15.0 (10.0–19.7) | 0.009 * |
| FTRV, % | 50.0 (49.9–55.0) | 43.6 (35.0–49.9) | 0.001 * |
* p < 0.05.
Univariable and multivariable Cox proportional hazard analysis for the MACE.
| Variates | Univariate | Multivariate | ||
|---|---|---|---|---|
| HR (95% CI) | HR (95% CI) | |||
| age | 0.971 (0.940–1.004) | 0.08 | ||
| WHO FC | 2.227 (1.039–4.774) | 0.04 | ||
| 6MWD | 0.996 (0.991–1.000) | 0.05 | ||
| IRTRV | 0.946 (0.881–1.017) | 0.13 | 0.930 (0.867–0.997) | 0.04 |
| CR | 0.421 (0.152–1.164) | 0.10 | ||
| mPAP | 1.037 (1.004–1.072) | 0.03 | 1.046 (1.012–1.081) | 0.007 |
MACE, major cardiovascular event; HR, hazard ratio; CI, confidence interval.